In one of the largest genomic studies of bone health to date, an international consortium has identified 14 novel genetic loci associated with bone mineral density (BMD), bringing the total number of known BMD-associated genetic variants to over 1,100. The study, published in Nature Genetics in early 2026, analyzed genomic data from 1.2 million individuals of diverse ancestry.
The GEnomics of Skeletal (GES) Consortium Study
The GES Consortium combined data from 69 cohorts across 32 countries, representing the largest meta-analysis of genome-wide association studies (GWAS) for bone mineral density. The research team performed DEXA scans on all participants and correlated genetic variants with measured BMD at the lumbar spine and femoral neck.
Key Findings
The study identified 14 novel genetic loci, including variants near genes involved in the RANKL signaling pathway, genes associated with chondrocyte development, and several genes previously linked to monogenic bone disorders. Individuals carrying 20 or more BMD-lowering alleles had a 2.7-fold increased risk of osteoporosis and a 1.9-fold increased risk of fracture compared to those with fewer than 10 such alleles.
Ancestry-Specific Findings
One of the study most significant contributions was identifying ancestry-specific genetic associations. Seven of the 14 novel loci were specific to non-European populations, highlighting the importance of diversity in genomic research. A variant near the AXIN1 gene was associated with lower BMD exclusively in East Asian populations.
Clinical and Therapeutic Implications
Polygenic risk scores incorporating the newly discovered variants demonstrated improved discriminative ability for osteoporosis. At the therapeutic level, the RANKL-associated loci suggest that fine-tuning RANKL inhibition could yield additional bone-protective benefits, while variants affecting WNT signaling pathways point to novel drug targets.
Future Directions
The consortium plans to expand its analysis to include functional genomics data from bone tissue to better understand how the identified variants influence bone biology at a cellular level.
Reference: GES Consortium, Nature Genetics, February 2026.
